BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,902,476 | -10.3% | 615,571 | +7.5% | 0.01% | -6.7% |
| Q2 2023 | $46,725,703 | +10.5% | 572,456 | +0.4% | 0.02% | +7.1% |
| Q1 2023 | $42,277,071 | +91375.2% | 569,893 | +2.2% | 0.01% | 0.0% |
| Q4 2022 | $46,217 | -99.9% | 557,606 | +291.1% | 0.01% | -12.5% |
| Q3 2022 | $40,491,000 | -16.6% | 142,569 | +1.8% | 0.02% | -5.9% |
| Q2 2022 | $48,528,000 | -26.3% | 140,002 | -7.9% | 0.02% | -15.0% |
| Q1 2022 | $65,833,000 | -16.9% | 152,011 | -0.7% | 0.02% | -16.7% |
| Q4 2021 | $79,214,000 | +5.2% | 153,132 | -1.4% | 0.02% | 0.0% |
| Q3 2021 | $75,299,000 | +15.1% | 155,380 | +7.0% | 0.02% | +14.3% |
| Q2 2021 | $65,407,000 | +2.2% | 145,271 | -13.4% | 0.02% | 0.0% |
| Q1 2021 | $64,017,000 | +17.6% | 167,678 | -2.2% | 0.02% | +5.0% |
| Q4 2020 | $54,442,000 | +35.7% | 171,446 | +5.8% | 0.02% | +17.6% |
| Q3 2020 | $40,124,000 | -4.1% | 161,974 | +2.2% | 0.02% | -5.6% |
| Q2 2020 | $41,849,000 | +25.4% | 158,503 | -9.9% | 0.02% | +5.9% |
| Q1 2020 | $33,376,000 | -23.2% | 176,016 | -11.0% | 0.02% | +6.2% |
| Q4 2019 | $43,433,000 | +8.0% | 197,868 | -3.7% | 0.02% | 0.0% |
| Q3 2019 | $40,198,000 | -8.3% | 205,432 | -2.3% | 0.02% | -5.9% |
| Q2 2019 | $43,825,000 | +6.2% | 210,207 | +1.1% | 0.02% | +6.2% |
| Q1 2019 | $41,276,000 | +36.7% | 207,892 | -0.4% | 0.02% | +14.3% |
| Q4 2018 | $30,201,000 | -30.2% | 208,701 | -1.5% | 0.01% | -12.5% |
| Q3 2018 | $43,253,000 | +37.5% | 211,911 | -0.3% | 0.02% | +23.1% |
| Q2 2018 | $31,455,000 | -1.1% | 212,609 | +1.0% | 0.01% | 0.0% |
| Q1 2018 | $31,806,000 | +20.8% | 210,580 | +3.6% | 0.01% | +18.2% |
| Q4 2017 | $26,323,000 | +9.5% | 203,188 | +2.2% | 0.01% | 0.0% |
| Q3 2017 | $24,046,000 | +6.4% | 198,911 | +3.5% | 0.01% | +10.0% |
| Q2 2017 | $22,590,000 | +18.2% | 192,251 | +2.2% | 0.01% | +11.1% |
| Q1 2017 | $19,119,000 | +3.2% | 188,094 | +4.4% | 0.01% | 0.0% |
| Q4 2016 | $18,531,000 | -8.0% | 180,205 | -2.1% | 0.01% | -18.2% |
| Q3 2016 | $20,145,000 | +2.8% | 183,983 | +5.9% | 0.01% | 0.0% |
| Q2 2016 | $19,587,000 | +28.2% | 173,713 | +7.5% | 0.01% | +22.2% |
| Q1 2016 | $15,280,000 | +9.1% | 161,650 | +3.9% | 0.01% | 0.0% |
| Q4 2015 | $14,009,000 | +10.4% | 155,643 | +13.4% | 0.01% | +12.5% |
| Q3 2015 | $12,691,000 | -2.9% | 137,269 | +3.5% | 0.01% | 0.0% |
| Q2 2015 | $13,064,000 | +8.3% | 132,671 | +10.3% | 0.01% | 0.0% |
| Q1 2015 | $12,064,000 | +19.5% | 120,294 | +10.1% | 0.01% | +14.3% |
| Q4 2014 | $10,092,000 | – | 109,214 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |